InTune Workspace - San Jose Territory

✨ Recommended

Ojjaara Sales

45 sales

vs Goal: 48 sales | QTD

↓ 7.8% vs goal

✨ Recommended

Market Share

21.6% #4 position

vs National: 25.3% | QTD

↓ 1.20pp vs prior quarter

✨ Recommended

New Patient Starts

46 starts

vs Eligible: 856 patients | QTD

↓ 4.2% vs prior quarter

✨ Recommended

Call Activity

1.7 calls/day

vs Goal: 1.5 calls/day | QTD

↑ 12% vs prior quarter

How is my brand performing?

3 New Insights

✨ Recommended

Sales Goal Attainment is trending below target

Territory delivered 45 units against 48-unit goal, representing a -6.3% shortfall. Performance gap widened from -3% (prior quarter) to current -6.3%, indicating accelerating underperformance.

Source: Specialty Pharmacy (QTD) Jan 2026

✨ Recommended

Central Mo is performing below National Average

Ojjaara market share declined from 22.8% to 21.6% (Q4 2024), while national average holds at 25.3%. Historical trend shows consistent 2.5-2.7pp gap persisting over past year.

Source:DDD (QTD) Jan 2026

✨ Recommended

New Patient Starts has started Declining in San Jose Territory

Conversion rate dropped to 5.4% (46 starts from 856 eligible), down from 5.7% eight weeks ago. Eligible pool grew 1.8% while starts declined 4.2%, confirming conversion barrier not patient availability.

Source: IQVIA (QTD) Jan 2026

Which HCPs show performance concerns?

3 New Insights

What is my territory payer mix and access status?

3 New Insights

✨ Recommended

Commercial & HIX dominate at 46.6% combined

Commercial payer mix increased from 22.8% to 24.4% over past year (+1.6pp), while Medicare share declined from 17.2% to 15.6% (-1.6pp). HIX maintained stable 22.2%, creating favorable private payer concentration for premium pricing strategies.

Source: IQVIA Claims Data (QTD) Jan 2026

✨ Recommended

Only 22% unrestricted access - majority face barriers

Unrestricted access decreased from 24.1% to 22.2% over past 6 months (-1.9pp), while PA requirements grew from 13.8% to 15.6% (+1.8pp). Combined barrier rate (PA + Step + Not Covered) now affects 53.4% of territory patient base.

Source: IQVIA Access Data (C6M) Jan 2026

✨ Recommended

PA approval rates declining quarter-over-quarter

PA approval rate dropped from 73% (Q3 2024) to 67% (Q4 2024), with average processing time increasing from 5.8 to 12.3 days. Denial rate for 2L use specifically increased 34% vs prior quarter, directly correlating with new starts decline.

Source: IQVIA Access Data (C6M) Jan 2026

Your top 8% of HCPs are going dark—and taking 40% of volume with them

1 New Insight

Only 12 HCPs are Tier A, but 5 have had zero contact in 45+ days. Those 5 alone represent 847 patients and an estimated $2.1M at risk. Dr. Thompson (47 days, 156 patients) and Dr. Chen (62 days) are the highest-leverage re-engagement targets; one re-engaged Tier A typically unlocks 3–4x the ROI of a mid-tier call.

Source: Veeva CRM (QTD) Jan 2026

Show By Days since last call Filter By Values Competitor Select

Customer ID ↑	Customer Name	Tier	Address	City	State	Zip	SP+SD Volume (Curr)	SP+SD Volume (Prev)	Total Calls	Total INPR Calls	F2F Calls	Virtual Calls	Phone Calls	Others Calls	RTE Sent	Last Call Date	Last Call Mode	Priority	Barriers
CUST-00001	Dr. Karen Allen	Tier 1	101 Main St	San Jose	CA	95101	21	13	11	12	1	1	1	1	1	01/28/2026	Virtual	First	Coverage / reimbursement
CUST-00002	Dr. Michael Chen	Tier 3	102 Main St	San Jose	CA	95102	21	16	14	15	2	2	2	0	2	01/25/2026	Phone	Second	Competitive messaging
CUST-00007	Dr. Emily Roberts	Tier 2	107 Main St	San Jose	CA	95107	21	16	14	15	2	3	1	1	1	01/13/2026	Virtual	First	New indication awareness
CUST-00012	Dr. Daniel Brown	Tier 3	112 Main St	San Jose	CA	95112	21	16	14	15	2	0	0	0	0	12/28/2025	F2F	Second	Samples / dosing
CUST-00017	Dr. Rachel Green	Tier 1	117 Main St	San Jose	CA	95117	21	16	14	15	2	1	5	1	2	12/13/2025	Phone	First	Guideline updates
CUST-00022	Dr. Jason Miller	Tier 3	122 Main St	San Jose	CA	95122	21	16	14	15	2	2	4	0	1	11/28/2025	Virtual	Second	Reintroduce brand
CUST-00027	Dr. Christina Young	Tier 2	127 Main St	San Jose	CA	95127	21	16	14	15	2	3	3	1	0	11/13/2025	F2F	First	Competitive messaging
CUST-00032	Dr. Nathan Evans	Tier 3	132 Main St	San Jose	CA	95132	21	16	14	15	2	0	2	0	2	10/25/2025	Phone	Second	KOL event invite
CUST-00006	Dr. David Park	Tier 3	106 Main St	San Jose	CA	95106	18	13	11	12	1	2	0	0	0	01/15/2026	F2F	Second	Formulary / access
CUST-00011	Dr. Amanda Foster	Tier 2	111 Main St	San Jose	CA	95111	18	13	11	12	1	3	5	1	2	01/01/2026	Phone	First	Combination therapy data

Veeva CRM

Ojjaara Sales

Market Share

New Patient Starts

Call Activity

How is my brand performing?

Sales Goal Attainment is trending below target

Central Mo is performing below National Average

New Patient Starts has started Declining in San Jose Territory

Which HCPs show performance concerns?

Bottom 5 HCPs by declining

HCPs with no recent contact

Engagement quality erosion in Strategic Accounts

What is my territory payer mix and access status?

Commercial & HIX dominate at 46.6% combined

Only 22% unrestricted access - majority face barriers

PA approval rates declining quarter-over-quarter

Your top 8% of HCPs are going dark—and taking 40% of volume with them

Ojjaara Sales

Market Share

New Patient Starts

Call Activity

How is my brand performing?

Sales Goal Attainment is trending below target

Central Mo is performing below National Average

New Patient Starts has started Declining in San Jose Territory

Which HCPs show performance concerns?

Bottom 5 HCPs by declining

HCPs with no recent contact

Engagement quality erosion in Strategic Accounts

What is my territory payer mix and access status?

Commercial & HIX dominate at 46.6% combined

Only 22% unrestricted access - majority face barriers

PA approval rates declining quarter-over-quarter

Your top 8% of HCPs are going dark—and taking 40% of volume with them

Add to Collection